# A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)

> **NCT00318136** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00318136
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2010-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318136, "A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00318136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*